Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL194908 | 0.80 | KDM4E (0.42) | KDM4EHSD17B10ALDH1A1GAAHPGD | |
| SCHEMBL194725 | 0.68 | ALDH1A1 (0.54) | KDM4EHSD17B10ALDH1A1GAAHPGD | |
| SCHEMBL194128 | 0.66 | AXL (0.45) | KDM4EHSD17B10ALDH1A1GAAKMT2A | |
| SCHEMBL13182042 | 0.66 | PTGES (0.43) | KDM4EHSD17B10ALDH1A1GAAMEN1 | |
| SCHEMBL194064 | 0.64 | KDM4E (0.41) | KDM4EHSD17B10ALDH1A1GAAHPGD | |
| SCHEMBL15996314 | 0.64 | AR (0.48) | KDM4EHSD17B10ALDH1A1GAAHPGD | |
| SCHEMBL10278516 | 0.64 | AR (0.43) | KDM4EHSD17B10ALDH1A1GAAHPGD | |
| SCHEMBL12755314 | 0.63 | NR3C1 (0.39) | KDM4EHSD17B10ALDH1A1GAAHPGD | |
| SCHEMBL13365184 | 0.63 | KDM4E (0.36) | KDM4EHSD17B10ALDH1A1GAAHPGD | |
| SCHEMBL13334392 | 0.63 | KDM4E (0.36) | KDM4EHSD17B10ALDH1A1GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12351553-B2 | Process for producing 5-aryl-1H-pyrolle-3-carbonitrile compounds by dehalogenation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-07-08 | — | — | US | disclosed |
| US-20230088365-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-03-23 | — | — | US | disclosed |
| US-11498898-B2 | Process for producing pyrrole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-11-15 | — | — | US | disclosed |
| CN-114835619-A | Process for preparing azole compounds | 武田药品工业株式会社 | 2022-08-02 | — | — | CN | disclosed |
| EP-3929187-A2 | PROCESS FOR PRODUCING PYRROLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2021-12-29 | — | — | EP | disclosed |
| US-20210070705-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-11 | — | — | US | disclosed |
| US-10844011-B2 | Process for producing pyrrole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-11-24 | — | — | US | disclosed |
| US-20190127324-A1 | 5-ARYL-1H-PYRROLE-3-CARBONITRILE AND A PHARMACEUTICAL PRODUCT USING THE SAME | TAKEDA PHARMACEUTICALS CO (JP) | 2019-05-02 | — | — | US | disclosed |
| US-10173977-B2 | 5-aryl-1H-pyrrole-3-carbonitrile and a pharmaceutical product using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-01-08 | — | — | US | disclosed |
| US-20180009746-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-01-11 | — | — | US | disclosed |
| US-9266831-B2 | Process for producing pyrrole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-02-23 | — | — | US | disclosed |
| US-9266831-B2 | Process for producing pyrrole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-02-23 | — | — | US | disclosed |
| US-20140303378-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2014-10-09 | — | — | US | disclosed |
| US-20140303378-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2014-10-09 | — | — | US | disclosed |
| US-8822694-B2 | Process for producing pyrrole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-02 | — | — | US | disclosed |
| US-8822694-B2 | Process for producing pyrrole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-02 | — | — | US | disclosed |
| EP-2402313-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2012-01-04 | — | — | EP | disclosed |
| US-20110306769-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-15 | — | — | US | disclosed |
| US-20110306769-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-15 | — | — | US | disclosed |
| WO-2010098351-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | 武田薬品工業株式会社 (JP) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070705-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | DHPS, STS, HPD | KDM4E 222/4885HSD17B10 1475/4885ALDH1A1 1184/4885 |
| US-12351553-B2 | Process for producing 5-aryl-1H-pyrolle-3-carbonitrile compounds by dehalogenation | CYP51A1, PAH, HPD | KDM4E 807/4885HSD17B10 98/4885ALDH1A1 1045/4885 |
| US-20230088365-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | DHPS, STS, HPD | KDM4E 222/4885HSD17B10 1475/4885ALDH1A1 1184/4885 |
| US-11498898-B2 | Process for producing pyrrole compound | DHPS, STS, HPD | KDM4E 222/4885HSD17B10 1475/4885ALDH1A1 1184/4885 |
| US-20180009746-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | DHPS, STS, HPD | KDM4E 222/4885HSD17B10 1475/4885ALDH1A1 1184/4885 |
| US-20190127324-A1 | 5-ARYL-1H-PYRROLE-3-CARBONITRILE AND A PHARMACEUTICAL PRODUCT USING THE SAME | CYP3A5, CYP3A4, CBR3 | KDM4E 420/4885HSD17B10 1220/4885ALDH1A1 467/4885 |
| US-20140303378-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | DHPS, STS, HPD | KDM4E 222/4885HSD17B10 1475/4885ALDH1A1 1184/4885 |
| US-10844011-B2 | Process for producing pyrrole compound | DHPS, STS, HPD | KDM4E 222/4885HSD17B10 1475/4885ALDH1A1 1184/4885 |
| US-20110306769-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | DHPS, STS, HPD | KDM4E 222/4885HSD17B10 1475/4885ALDH1A1 1184/4885 |
| US-10173977-B2 | 5-aryl-1H-pyrrole-3-carbonitrile and a pharmaceutical product using the same | CYP3A5, CYP3A4, CBR3 | KDM4E 420/4885HSD17B10 1220/4885ALDH1A1 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.